Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.

doi:10.1097/JTO.0b013e318168c7d0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2008

Ludovini Vienna, Pistola Lorenza, Gregorc Vanesa, Floriani Irene, Rulli Eliana, Piattoni Simonetta, Di Carlo Luciana, Semeraro Antonia, Darwish Samir, Tofanetti Francesca Romana, Stocchi Lucia, Mihaylova Zhasmina, Bellezza Guido, Del Sordo Rachele, Daddi Giuliano, Crinò Lucio, Tonato Maurizio

Abstract excerpt

INTRODUCTION: This prospective study examined association between circulating plasma DNA, microsatellite alterations (MA), p53 mutations with time to relapse and survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). METHODS: Plasma samples, adjacent lung tissue, and lung tumor tissue specimens were collected from consecutive patients with stage I-III NSCLC. Blood samples of 66 matched...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Large Cell

Share to Carcinoma, Non-Small-Cell Lung

Share to Carcinoma, Squamous Cell

Share to Disease-Free Survival

Share to Lymph Nodes

Share to Neoplasm Recurrence, Local

Share to Polymorphism, Single-Stranded Conformational

Source

Open in PubMed

Identifiers

PMID: 18379354
DOI: 10.1097/JTO.0b013e318168c7d0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.PMID 18379354Read ↗

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Semantic proximity Read ↗

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.Semantic proximity Read ↗

Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.Semantic proximity Read ↗

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read ↗

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutationsSemantic proximity Read ↗

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?Semantic proximity Read ↗

Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancers.Semantic proximity Read ↗

Microsatellite alterations in plasma DNA of small cell lung cancer patientsSemantic proximity Read ↗

Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients as a Potential Screening and Prognostic ToolSemantic proximity Read ↗

Detecting lung cancer in plasma with the use of multiple genetic markers.Semantic proximity Read ↗

Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.